Research progress of TRIM14 in malignant tumors

doi:10.3760/cma.j.issn.1673-422X.2018.12.006

Abstract

Abstract: Tripartite motifcontaining 14 (TRIM14) is a member of tripartite motif family. Regulating innate immune response and affecting cell differentiation are the main physiological functions of TRIM14. It is reported TRIM14 expresses in various tumors such as nonsmall cell lung cancer, breast cancer, hepatocellular carcinoma, osteosarcoma and oral squamous cell carcinoma. The proliferation, invasion, metastasis, drug resistance of malignant tumors and the prognosis of patients with cancer can be affected via different mechanisms of TRIM14.

Key words: Neoplasms, Cell proliferation, Neoplasms metastasis, Tripartite motif-containing 14

Yang Zhixian, Hou Fei, Li Haoyu, Deng Zhiyong. Research progress of TRIM14 in malignant tumors[J]. Journal of International Oncology, 2018, 45(12): 731-734.

References

［1］ Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66(2): 115132. DOI: 10.3322/caac.21338. ［2］ Hirose S, Nishizumi H, Sakano H. Pub, a novel PU.1 binding protein, regulates the transcriptional activity of PU.1［J］. Biochem Biophys Res Commun, 2003, 311(2): 351360. DOI: 10.1016/j.bbrc.2003.09.212. ［3］杨星星, 王凯, 陈晓娟, 等. 线粒体抗病毒信号蛋白(MAVS)在宿主天然免疫信号通路中的调节作用［J］. 生物化学与生物物理进展, 2013, 40(5): 397405. DOI: 10.3724/SP.J.1206.2012.00513. ［4］ Zhou Z, Jia X, Xue Q, et al. TRIM14 is a mitochondrial adaptor that facilitates retinoic acidinducible geneⅠlike receptormediated innate immune response［J］. Proc Natl Acad Sci U S A, 2014, 111(2): E245E254. DOI: 10.1073/pnas.1316941111. ［5］周卓, 贾雪, 薛清华, 等. TRIM14蛋白参与抗病毒天然免疫反应［C］. 第九届全国免疫学学术大会, 2014, 中国山东济南. ［6］ Nenasheva VV, Kovaleva GV, Uryvaev LV, et al. Enhanced expression of trim14 gene suppressed Sindbis virus reproduction and modulated the transcription of a large number of genes of innate immunity［J］. Immunol Res, 2015, 62(3): 255262. DOI: 10.1007/s1202601586531. ［7］ Wang S, Chen Y, Li C, et al. TRIM14 inhibits hepatitis C virus infection by SPRY domaindependent targeted degradation of the viral NS5A protein［J］. Sci Rep, 2016, 6: 323336. DOI: 10.1038/srep32336. ［8］ Tan P, He L, Cui J, et al. Assembly of the WHIPTRIM14PPP6C mitochondrial complex promotes RIGⅠmediated antiviral signaling［J］. Mol Cell, 2017, 68(2): 293307.e5. DOI: 10.1016/j.molcel.2017.09.035. ［9］ Nenasheva VV, Kovaleva GV, Khaidarova NV, et al. Trim14 overexpression causes the same transcriptional changes in mouse embryonic stem cells and human HEK293 cells［J］. In Vitro Cell Dev Biol Anim, 2014, 50(2): 121128. DOI: 10.1007/s1162601396834. ［10］王权, 孙文逵, 施毅. 转录因子PU.1与机体免疫功能的相关性及其研究进展［J］. 医学研究生学报, 2013, 26(10): 10961100. DOI: 10.16571/j.cnki.10088199.2013.10.004. ［11］ Su X, Wang J, Chen W, et al. Overexpression of TRIM14 promotes tongue squamous cell carcinoma aggressiveness by activating the NFkappaB signaling pathway［J］. Oncotarget, 2016, 7(9): 99399950. DOI: 10.18632/oncotarget.6941. ［12］ Wang Y, Lin Z, Sun L, et al. Akt/Ezrin Tyr353/NFkappaB pathway regulates EGFinduced EMT and metastasis in tongue squamous cell carcinoma［J］. Br J Cancer, 2014, 110(3): 695705. DOI: 10.1038/bjc.2013.770. ［13］ Grille SJ, Bellacosa A, Upson J, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines［J］. Cancer Res, 2003, 63(9): 21722178. ［14］ Wang X, Guo H, Yao B, et al. miR15b inhibits cancerinitiating cell phenotypes and chemoresistance of cisplatin by targeting TRIM14 in oral tongue squamous cell cancer［J］. Oncol Rep, 2017, 37(5): 27202726. DOI: 10.3892/or.2017.5532. ［15］ Wang T, Ren Y, Liu R, et al. miR1955p suppresses the proliferation, migration, and invasion of oral squamous cell carcinoma by targeting TRIM14［J］. Biomed Res Int, 2017, 2017: 7378148. DOI: 10.1155/2017/7378148. ［16］ Xu G, Guo Y, Xu D, et al. TRIM14 regulates cell proliferation and invasion in osteosarcoma via promotion of the AKT signaling pathway［J］. Sci Rep, 2017, 7: 42411. DOI: 10.1038/srep42411. ［17］ Kong L, Schafer G, Bu H, et al. Lamin A/C protein is overexpressed in tissueinvading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway［J］. Carcinogenesis, 2012, 33(4): 751759. DOI: 10.1093/carcin/bgs022. ［18］ Daniele S, Costa B, Zappelli E, et al. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells［J］. Sci Rep, 2015, 5: 9956. DOI: 10.1038/srep09956. ［19］ Shen CC, Cui XY, He Y, et al. High phosphorylation status of AKT/mTOR signal in DESI2reduced pancreatic ductal adenocarcinoma［J］. Pathol Oncol Res, 2015, 21(2): 267272. DOI: 10.1007/s1225301498173. ［20］ Chen J, Bai M, Ning C, et al. Gankyrin facilitates folliclestimulating hormonedriven ovarian cancer cell proliferation through the PI3K/AKT/HIF1alpha/cyclin D1 pathway［J］. Oncogene, 2016, 35(19): 25062517. DOI: 10.1038/onc.2015.316. ［21］ Yu GH, Li AM, Li X, et al. Bispecific antibody suppresses osteosarcoma aggressiveness through regulation of NFkappaB signaling pathway［J］. Tumour Biol, 2017, 39(6): 1010428317705572. DOI: 10.1177/1010428317705572. ［22］ Dong B, Zhang W. High levels of TRIM14 are associated with poor prognosis in hepatocellular carcinoma［J］. Oncol Res Treat, 2018, 41(3): 129134. DOI: 10.1159/000485625. ［23］ Hu G, Pen W, Wang M. TRIM14 promotes breast cancer cell proliferation by inhibiting apoptosis［J］. Oncol Res, 2018, In press. DOI: 10.3727/096504018X15214994641786. ［24］ Juin P, Geneste O, Gautier F, et al. Decoding and unlocking the BCL2 dependency of cancer cells［J］. Nat Rev Cancer, 2013, 13(7): 455465. DOI: 10.1038/nrc3538. ［25］ HamacherBrady A, Brady NR. Bax/Bakdependent, Drp1independent targeting of Xlinked inhibitor of apoptosis protein (XIAP) into inner mitochondrial compartments counteracts Smac/DIABLOdependent effector caspase activation［J］. J Biol Chem, 2015, 290(36): 2200522018. DOI: 10.1074/jbc.M115.643064. ［26］ Tai WT, Cheng AL, Shiau CW, et al. Signal transducer and activator of transcription 3 is a major kinaseindependent target of sorafenib in hepatocellular carcinoma［J］. J Hepatol, 2011, 55(5): 10411048. DOI: 10.1016/j.jhep.2011.01.047. ［27］艾美玲. TRIM14通过调控HBP通路抑制非小细胞肺癌细胞生长［D］. 南昌：南昌大学, 2016. ［28］ Ruan HB, Singh JP, Li MD, et al. Cracking the OGlcNAc code in metabolism［J］. Trends Endocrinol Metab, 2013, 24(6): 301309. DOI: 10.1016/j.tem.2013.02.002. ［29］ Yehezkel G, Cohen L, Kliger A, et al. Olinked betaNacetylglucosaminylation (OGlcNAcylation) in primary and metastatic colorectal cancer clones and effect of NacetylbetaDglucosaminidase silencing on cell phenotype and transcriptome［J］. J Biol Chem, 2012, 287(34): 2875528769. DOI: 10.1074/jbc.M112.345546. ［30］ Oikari S, Makkonen K, Deen AJ, et al. Hexosamine biosynthesis in keratinocytes: roles of GFAT and GNPDA enzymes in the maintenance of UDPGlcNAc content and hyaluronan synthesis［J］. Glycobiology, 2016, 26(7): 710722. DOI: 10.1093/glycob/cww019. ［31］ Hai J, Zhu CQ, Wang T, et al. TRIM14 is a putative tumor suppressor and regulator of innate immune response in nonsmall cell lung cancer［J］. Sci Rep, 2017, 7: 39692. DOI: 10.1038/srep39692.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.